Comparing the Expression Levels of GCG and FBN-1 in the Plasma of  Patients with Basal Cell Carcinoma (BCC) and Healthy Individuals

Maryam Keyfari  Alamdari; Abdolreza  Mohamadnia; Mohammad  Bayat; Masoume  Farhangiyan; Naghmeh  Bahrami

doi:10.18502/jcr.v12i2.19966

Maryam Keyfari Alamdari Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Abdolreza Mohamadnia Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, And Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Bayat Department of Oral and Maxillofacial Surgery, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
Masoume Farhangiyan Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Naghmeh Bahrami Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Tehran, Iran.

DOI: https://doi.org/10.18502/jcr.v12i2.19966

Keywords: Basal cell carcinoma; Glucagon gene (GCC); Fibrillin-1 (FBN-1); MicroRNA.

Abstract

Introduction: One of the most common types of skin cancer is basal cell carcinoma (BCC), which puts a big burden on the healthcare system. Direct and dermoscopic examinations are used to diagnose basal cell carcinoma. GCG is a protein-coding gene expressed in various cells throughout the body, including the small intestine, brain, and skin. Fibrillin-1 is an extracellular protein found in many body tissues. In this study, we compare the expression of GCG and FBN1 genes in the blood of patients with BCC and a healthy control group.

Materials and Methods: 1. Selection of patients and sampling. 2. Blood sampling of BCC patients and the control group. 3. Isolation of RNA from blood using an extraction kit. 4. Measurement of RNA concentration and purity. 5. cDNA synthesis and real-time PCR using a specific miRNA cDNA synthesis kit. 6. Statistical analysis

Results: The GCG biomarker was positive in 9 out of 15 patients in the group of patients with basal cell carcinoma (BCC). The rate of positivity for this biomarker in the group of healthy individuals was 4 out of 15, indicating a statistically significant difference between the two groups (P-value<0.001). The FBN1 biomarker was positive in 11 out of 15 patients with basal cell carcinoma (BCC). The rate of positivity for this biomarker in the group of healthy individuals was 5 out of 15 people, indicating a statistically significant difference between the two studied groups. (P-value<0.001).

Conclusion: The expression of GCG and FBN1 is significantly higher in patients with BCC compared to healthy individuals. Further studies can be done to ensure the role of these genes in the diagnosis of skin cancers.